comunicacio

Mutua Madrileña Foundation supports a Bellvitge project that will promote the clinical use of bioartificial kidneys

The study, led by Dr. Miguel Hueso, will help create alternatives to organ donation and dialysis for the treatment of chronic diseases, and the development of new drugs.

Mutua Madrileña Foundation supports a Bellvitge project that will promote the clinical use of bioartificial kidneys Read More »

Bellvitge contributes to a significant improvement in the treatment of hereditary angioedema

Researchers from Bellvitge University Hospital (HUB) and IDIBELL have participated in a clinical trial that has demonstrated the efficacy of sebetralstat, a new oral treatment for hereditary angioedema attacks.

Bellvitge contributes to a significant improvement in the treatment of hereditary angioedema Read More »

A genetic test will improve the diagnosis of a rare cancer predisposition syndrome in children

Researchers have developed a genetic test that will improve the diagnosis of CMMRD, a rare cancer predisposition syndrome in children. The analysis of only a selection of genetic segments allows this test to be fast and accessible to healthcare professionals.

A genetic test will improve the diagnosis of a rare cancer predisposition syndrome in children Read More »

Researchers discover biomarkers that predict response to immunotherapy in skin carcinoma

IDIBELL researchers have discovered a mechanism by which tumor cells respond differentially to various immunotherapies and have identified biomarkers that predict the response to these drugs. Published in Nature Communications, this finding would allow personalizing the treatment of skin carcinoma and thus increase the patients quality of life.

Researchers discover biomarkers that predict response to immunotherapy in skin carcinoma Read More »

Fecal microbiota transplantation emerges as a safe and effective alternative to antibiotics for C. difficile infection

150 recurrent cases of C. difficile in Catalonia could be treated with Fecal Microbiota Transplantation each year

Fecal microbiota transplantation emerges as a safe and effective alternative to antibiotics for C. difficile infection Read More »

Telemedicine improves follow-up of patients with advanced hematological treatments

Recent research by the Hematology and Digital Health groups of IDIBELL and ICO shows that the use of smart watches and mobile apps improves the follow-up of patients who have received a bone marrow transplant or CAR-T therapy.

Telemedicine improves follow-up of patients with advanced hematological treatments Read More »

The role of the epidermal growth factor receptor in chronic liver damage has been proven

Researchers from IDIBELL, CIBER and the Complutense University, led by Dr. Isabel Fabregat, link EGFR signaling to fibrotic and inflammatory processes in the liver. The findings, obtained with a mouse model, could be transferred to patients suffering from a fibrotic process.

The role of the epidermal growth factor receptor in chronic liver damage has been proven Read More »

More than a hundred experts meet in Barcelona to discuss the latest advances in the treatment of onco-haematological diseases

M. Carolina Florian and Alessandra Giorgetti, group leaders of the Regenerative Medicine Program at IDIBELL, are part of the organizing committee. The congress featured more than ten national and international speakers, and 135 participants.

More than a hundred experts meet in Barcelona to discuss the latest advances in the treatment of onco-haematological diseases Read More »

The IDIBELL and Institut Bellvitge Tandem consolidates its scientific education activities

The II Biomedicine Congress of the URIB, this year on research ethics and vaccines, has concluded the 2023/24 Tandem academic course. The 7th issue of Life&Science magazine is published, including an interview with Dr. Anna Veiga and a report on the ecological footprint of research.

The IDIBELL and Institut Bellvitge Tandem consolidates its scientific education activities Read More »

Scroll to Top